Abstracts tagged "Biomarkers"

Abstract Number: 645 • 2012 ACR/ARHP Annual Meeting
Altered Soluble Inflammatory Mediators Mark Impending Systemic Lupus Erythematosus Disease Flare in European-American Lupus Patients Who Receive Influenza Vaccination
Melissa E. Munroe¹, Jourdan R. Anderson², Joan T. Merrill³, Joel M. Guthridge⁴, Virginia C. Roberts⁴, Gillian M. Air⁵, Linda F. Thompson⁶ and Judith A. James⁷, ¹Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵Biochemistry, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶Immunobiology and Cancer, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁷Oklahoma Medical Research Foundation; University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background/Purpose: SLE is a multifaceted autoimmune disease denoted by immune dysregulation that contributes to increased morbidity and mortality in part due to infectious complications. Vaccination…
Abstract Number: L1 • 2012 ACR/ARHP Annual Meeting
A Randomized, Placebo-Controlled Phase 2 Study of ARRY-797 in Patients with Osteoarthritis Pain Refractory to NSAID Treatment Showed Statistically Significant Improvements in WOMAC Pain and in Biomarkers of Bone and Cartilage Degradation
Alan J. Kivitz¹, Shane G. Christensen², John Agaiby³, Egilius Spierings⁴, Julie Daves⁵, Roger Aitchison⁶, Stephen G. Miller⁷, Karsten Witt⁸ and Joseph Gimbel⁹, ¹Altoona Center for Clinical Research, Duncansville, PA, ²J. Lewis Research, Inc., Salt Lake City, UT, ³Clinical Investigation Specialists, Gurnee, IL, ⁴MedVadis Research Corporation, Watertown, MA, ⁵Clinical Operations, Array Biopharma, Inc., Boulder, CO, ⁶Biostatistics & Data Management, Array Biopharma, Inc., Boulder, CO, ⁷Translational Medicine, Array Biopharma, Inc., Boulder, CO, ⁸Clinical Sciences, Array Biopharma, Inc., Boulder, CO, ⁹Arizona Research Center, Phoenix, AZ
Background/Purpose: Osteoarthritis (OA) is the most common chronic joint disease and OA pain is a leading cause of work disability. p38 inhibition suppresses the production…
Abstract Number: 2251 • 2012 ACR/ARHP Annual Meeting
High Sensitivity C-Reactive Protein, Disease Activity and Cardiovascular Risk Factors in Systemic Lupus Erythematosus
Chi Chiu Mok¹, Daniel Birmingham², Ling Yin Ho¹ and Brad H. Rovin³, ¹Medicine, Tuen Mun Hospital, Hong Kong, Hong Kong, ²Medicine, Ohio State University Medical Center, Columbus, OH, ³Division of Nephrology, Ohio State University Medical Center, Columbus, OH

Background/Purpose: To study the level of high-sensitivity C-reactive protein (hsCRP) and its relationship with disease activity, damage and cardiovascular risk factors in patients with systemic…
Abstract Number: 1471 • 2012 ACR/ARHP Annual Meeting
Differential Expression of Hepatocyte Growth Factor (HGF) in Patients with Systemic Sclerosis-Associated Pulmonary Arterial Hypertension
Lorinda Chung¹, Catriona Cramb², William H. Robinson³, Virginia D. Steen⁴ and Roham T. Zamanian⁵, ¹Rheumatology, Stanford Univ Medical Center, Palo Alto, CA, ²VA Palo Alto Heatlh Care System and Stanford University, Palo Alto, CA, ³Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, ⁴Department of Rheumatology, Georgetown University Medical Center, Washington, DC, ⁵Stanford University, Palo Alto, CA
Background/Purpose: Pulmonary arterial hypertension (PAH) is one of the leading causes of death in patients with systemic sclerosis (SSc). Non-invasive biomarkers are needed to identify…
Abstract Number: 839 • 2012 ACR/ARHP Annual Meeting
Urinary Levels of High Mobility Group Box 1 Protein Are Elevated in Patients with Active Lupus Nephritis, and Correlate with Renal Histopathology
Irene Blanco¹, Neelakshi Jog², Chaim Putterman³, Iris Lee⁴ and Roberto Caricchio⁵, ¹Rheumatology, Albert Einstein College of Medicine, Bronx, NY, ²Rheumatology, Temple University, Philadelphia, PA, ³Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, ⁴Nephrology, Temple University, Philadelphia, PA, ⁵Medicine/Rheumatology, Temple University, Philadelphia, PA
Background/Purpose: High mobility group box 1 protein (HMGB-1) had been implicated in the pathogenesis of SLE and potentially lupus nephritis (LN). There is increased expression…
Abstract Number: 560 • 2012 ACR/ARHP Annual Meeting
Proteomic Profiling of Synovial Fluid Reveals Candidate Psoriatic Arthritis Biomarkers
Daniela Cretu¹, Ihor Batruch², Punit Saraon³, Dafna D. Gladman⁴, Fawnda Pellett⁵, Eleftherios Diamandis⁶ and Vinod Chandran⁷, ¹Department of Laboratory Medicine and Pathobiology, University of Toronto, Department of Laboratory Medicine and Pathobiology, Toronto, ON, Canada, ²Department of Pathology and Lab Medicine,, Mount Sinai Hospital, Toronto, ON, Canada, ³Department of Pathology and Lab Medicine, Mount Sinai Hospital, Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada, ⁴Division of Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ⁵Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁶Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada, ⁷Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada
Background/Purpose: Psoriatic arthritis (PsA) is a unique form of arthritis occurring in 30% of psoriasis patients. There is a high prevalence of undiagnosed PsA in…
Abstract Number: 2261 • 2012 ACR/ARHP Annual Meeting
Ovarian Reserve Markers in Reproductive Age Women with Systemic Lupus Erythematosus
Olívio B. Malheiro¹, Carolina P. Rezende¹, Gilda A. Ferreira² and Fernando M. Reis¹, ¹Obstetrics and Gynecology, Federal University of Minas Gerais, Belo Horizonte, Brazil, ²Locomotor System Medicine, Federal University of Minas Gerais, Belo Horizonte, Brazil
Background/Purpose: Systemic lupus erythematosus (SLE) is a multisystem disease, which affects mostly women at reproductive age, and can promote premature ovarian dysfunction related to factors…
Abstract Number: 1473 • 2012 ACR/ARHP Annual Meeting
Sub-Analysis of ELF Score Biomarkers Components Indicates a Specific Correlation with Different Organ Involvement in Systemic Sclerosis
Giuseppina Abignano¹, Giovanna Cuomo², Maya H. Buch³, William M. Rosenberg⁴, Gabriele Valentini⁵, Paul Emery⁶ and Francesco Del Galdo⁷, ¹Chapel Allerton Hospital Leeds Insitute of Molecular medicine, Division of Rheumatic and Musculoskeletal Disease, University of Leeds, Leeds Institute of Molecular Medicine and LMBRU, Leeds, United Kingdom, ²Department of Internal and Experimental Medicine, Second University of Naples, Naples, Italy, ³Division of Rheumatic and Musculoskeletal Disease, University of Leeds, Leeds Institute of Molecular Medicine and LMBRU, Leeds, United Kingdom, ⁴Centre for Hepatology - UCL, London, United Kingdom, ⁵Rheumatology/Int Med, Second University of Naples, Rheumatology Unit, Naples, Italy, ⁶Division of Rheumatic and Musculoskeletal Disease, University of Leeds, Leeds Institute of Molecular Medicine and NIHR LMBRU, Leeds, United Kingdom, ⁷Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
Background/Purpose: A recent large multicenter study has identified an algorithm, known as Enhanced Liver Fibrosis (ELF), by combining the serum concentrations of amino-terminal propeptide of procollagen type III (PIIINP),…
Abstract Number: 840 • 2012 ACR/ARHP Annual Meeting
Do Serum Hepcidin 25 Levels Predict SLE Renal or Non-Renal Flares?
Alexandra Friedman¹, Nicholas Young², Paul Jensen³, Xiaolin Zhang⁴, Wael N. Jarjour⁵, Brad H. Rovin⁴, Daniel Birmingham³, Lee Hebert³ and Stacy P. Ardoin⁶, ¹Immunology and Rheumatology, The Ohio State University Wexner Medical Center, Columbus, OH, ²Immunology and Rheumatology, The Ohio State University Medical Center, Columbus, OH, ³Medicine, Ohio State University Medical Center, Columbus, OH, ⁴Division of Nephrology, Ohio State University Medical Center, Columbus, OH, ⁵Dept of Rheumatology/Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, ⁶Pediatric & Adult Rheumatology, Ohio State University College of Medicine, Columbus, OH
Background/Purpose: Biomarkers are needed which can accurately predict systemic lupus erythematosus (SLE) flare, allowing tailoring of immunosuppressive therapy to minimize disease damage and medication toxicity.…
Abstract Number: 568 • 2012 ACR/ARHP Annual Meeting
14-3-3 Eta Is a Modifiable Serum Biomarker That Marks Adalimumab Response in Psoriatic Arthritis
Anthony Marotta¹, A. W van Kuijk², Walter P. Maksymowych³ and Paul Peter Tak⁴, ¹Augurex Life Sciences Corp, North Vancouver, BC, Canada, ²Clinical Immunology / Rheumatology, Academic Medical Centre/University of Amsterdam, Amsterdam, Netherlands, ³Department of Medicine, University of Alberta, Edmonton, AB, Canada, ⁴Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands
Background/Purpose: 14-3-3 eta is a synovial-derived biomarker whose serum expression is independently associated with joint damage in RA and PsA. We previously reported that 14-3-3…
Abstract Number: 2162 • 2012 ACR/ARHP Annual Meeting
Correlation of A Multi-Biomarker Disease Activity (VECTRA™ DA) Score with Clinical Disease Activity and Its Components with Radiographic Progression in Rheumatoid Arthritis Patients Treated with Tofacitinib
Kunihiro Yamaoka¹, Satoshi Kubo¹, Koshiro Sonomoto¹, Shintaro Hirata¹, Guy Cavet², Rebecca Bolce², Michael W. Rowe², David Chernoff², Nadine Defranoux², Kazuyoshi Saito¹ and Yoshiya Tanaka¹, ¹The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²Crescendo Bioscience Inc., South San Francisco, CA
Background/Purpose: A multi-biomarker disease activity (MBDA) score has been developed for evaluation of disease activity of rheumatoid arthritis (RA) to complement clinical assessment and to…
Abstract Number: 1329 • 2012 ACR/ARHP Annual Meeting
Differential Effect of 4 and 8 Mg/Kg Tocilizumab in Combination with Methotrexate On Serum Biomarkers of Cartilage, Connective Tissue and Bone Turnover
Anne C. Bay-Jensen¹, Inger Byrjalsen², Andrew Kenwright³, Thierry Sornasse⁴, Claus Christiansen⁵ and Morten Asser Karsdal⁶, ¹Cartilage Biomarkers and Research, Nordic Bioscience, Herlev, Denmark, ²Research & Development, Nordic Bioscience, Herlev, Denmark, ³Roche, Welwyn Garden City, United Kingdom, ⁴Genentech, South San Francisco, ⁵CCBR, Ballerup, Denmark, ⁶Nordic Bioscience A/S, Herlev, Denmark
Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by poly-articular inflammation, cartilage loss, synovial inflammation, subchondral bone erosion, and joint space narrowing. In…
Abstract Number: 850 • 2012 ACR/ARHP Annual Meeting
Elevation of KL-6 At Early Disease Course Predicts Subsequent Deterioration of Pulmonary Function in Patients with Systemic Sclerosis and Interstitial Lung Disease
Masataka Kuwana¹, Tsutomu Takeuchi² and Junichi Kaburaki³, ¹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ²Rheumatology, Keio University School of Medicine, Tokyo, Japan, ³Dept of Internal Med, Shinakasaka Clinic, Tokyo, MI, Japan
Background/Purpose: Interstitial lung disease (ILD) is the leading cause of morbidity and mortality in patients with systemic sclerosis (SSc). However, only a subset of SSc…
Abstract Number: 430 • 2012 ACR/ARHP Annual Meeting
Comprehensive Microrna Analysis Identifies Mir-24, Mir-26a, and Mir-125a-5p As Plasma Biomarkers for Rheumatoid Arthritis
Koichi Murata¹, Moritoshi Furu², Hiroyuki Yoshitomi³, Masahiro Ishikawa¹, Hideyuki Shibuya¹, Hiromu Ito² and Shuichi Matsuda¹, ¹Department of Orthopaedic Surgery, Kyoto University Graduate School of Medicine, Kyoto, Japan, ²Department of the Control for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ³Department of Innovation Center for Immunoregulation Technologies and Drugs, Kyoto University Graduate School of Medicine, Kyoto, Japan
Background/Purpose: MicroRNAs (miRNAs) are present in human plasma in a stable form despite the endogenous RNase activity. Plasma miRNAs are non-invasive biomarker for cancer detection…
Abstract Number: 2166 • 2012 ACR/ARHP Annual Meeting
Identification of Serological Biomarker Profiles Associated with Response to IL-6 Intervention in Rheumatoid Arthritis
Morten Asser Karsdal¹, Anne C. Bay-Jensen², Inger Byrjalsen³, Andrew Kenwright⁴, Adam Platt⁴, Thierry Sornasse⁵ and Claus Christiansen⁶, ¹Nordic Bioscience A/S, Herlev, Denmark, ²Cartilage Biomarkers and Research, Nordic Bioscience, Herlev, Denmark, ³Research & Development, Nordic Bioscience, Herlev, Denmark, ⁴Roche, Welwyn Garden City, United Kingdom, ⁵Product Development Immunology, Genentech, Inc., South San Francisco, USA, San Fransisco, CA, ⁶CCBR, Ballerup, Denmark
Background/Purpose: RA is characterized by poly-articular synovial inflammation, cartilage loss and erosion of subchondral bone. It is critical to diagnose and effectively treat the disease…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].